Whitehaven Coal’s A$1bn Winchester South project clears major court hurdle but approvals remain outstanding
Read More Pharma Industry News Zelira Therapeutics (ASX:ZLD) secures $33m to advance HOPE 1 autism therapy through U.S. FDA trials Find out how Zelira’s US$33M SPV deal with ThirdGate Capital is reshaping its FDA strategy for HOPE 1 and shaking up the autism biotech space. bySrinathJanuary 16, 2026